- Stocks /
- Atomo Diagnostics Ltd (ASX: AT1) /
Atomo Diagnostics Ltd (ASX: AT1) Share Price and News
Price
$0.024
Movement
0.001 (-4.0%)
as at 9 Oct 11:59am (20 mins delayed)
52 Week Range
$0.014 - $0.032
1 Year Return
+20.0%
Atomo Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Earnings Yield
N/A
Franking
-
Dividend per share
N/A
Year To Date Return
52.63%
Shares Outstanding
810.18 million
Earnings per share
-0.008
Share Price
$0.024
Day Change
0.001 (-4.0%)
52 Week Range
$0.014 - $0.032
Yesterday's Close
$0.025
Today's Open
$0.0255
Days Range
$0.024 - $0.026
Volume
1,667,840
Avg. Volume (1 month)
2,165,285
Turnover
$41,736
as at 9 Oct 11:59am
Atomo Diagnostics Ltd (ASX: AT1)
Latest News

Share Gainers
Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!
| Bernd Struben

Share Gainers
Guess which ASX pharmaceutical stock just rocketed 122%!
| Bernd Struben

Healthcare Shares
3 ASX healthcare shares rocketing 20% to 100% today
| James Mickleboro

Earnings Results
3 ASX healthcare shares punished following full-year results
| Zach Bristow

Earnings Results
Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings
| Monica O'Shea

Coronavirus News
Why are ASX COVID test shares climbing today?
| Monica O'Shea

Healthcare Shares
Here's why the Atomo (ASX:AT1) share price is rocketing 17% today
| Aaron Teboneras

Healthcare Shares
Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?
| Brooke Cooper

Healthcare Shares
Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?
| Zach Bristow

Healthcare Shares
Is AM Diagnostics listed on the ASX?
| Brooke Cooper

Share Fallers
Why Afterpay, Atomo, Opthea, & Sealink shares are falling today
| James Mickleboro

Share Market News
Here's why the Atomo (ASX:AT1) share price is crashing 9% today
| James Mickleboro
AT1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
30th Sep 2025 2025-09-30T12:32:48 | 2025 Notice of Annual General Meeting | YesNo | 12:32pm | 24 | 1.3M |
25th Sep 2025 2025-09-25T16:18:29 | Notification regarding unquoted securities - AT1 | YesNo | 4:18pm | 6 | 18k |
24th Sep 2025 2025-09-24T15:32:29 | Response to ASX Price Query | YesNo | 3:32pm | 3 | 316k |
24th Sep 2025 2025-09-24T13:24:43 | Pause in Trading | YesNo | 1:24pm | 1 | 116k |
9th Sep 2025 2025-09-09T09:46:48 | Atomo Appoints Chair | YesNo | 9:46am | 1 | 62k |
29th Aug 2025 2025-08-29T09:35:46 | Atomo Investor Webinar Presentation | YesNo | 9:35am | 1 | 63k |
29th Aug 2025 2025-08-29T09:34:21 | 2025 Appendix 4G and Corporate Governance Statement | YesNo | 9:34am | 29 | 2.5M |
29th Aug 2025 2025-08-29T09:34:01 | FY25 Results Presentation | YesNo | 9:34am | 26 | 5.2M |
29th Aug 2025 2025-08-29T09:30:36 | 2025 Appendix 4E and Annual Report | YesNo | 9:30am | 56 | 878k |
21st Aug 2025 2025-08-21T10:33:21 | Update on Indicated Pascal Supply for FebriDx | YesNo | 10:33am | 3 | 227k |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
AT1 Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Oct 2025 | $0.03 | $0.00 | 0.00% | 1,566,207 | $0.03 | $0.03 | $0.03 |
07 Oct 2025 | $0.03 | $0.00 | 0.00% | 773,104 | $0.03 | $0.03 | $0.03 |
06 Oct 2025 | $0.03 | $0.00 | 0.00% | 1,432,368 | $0.03 | $0.03 | $0.03 |
03 Oct 2025 | $0.03 | $0.00 | 0.00% | 471,316 | $0.03 | $0.03 | $0.03 |
02 Oct 2025 | $0.03 | $0.00 | 0.00% | 816,226 | $0.03 | $0.03 | $0.03 |
01 Oct 2025 | $0.03 | $0.00 | 0.00% | 543,441 | $0.03 | $0.03 | $0.03 |
30 Sep 2025 | $0.03 | $0.00 | 0.00% | 3,751,468 | $0.03 | $0.03 | $0.03 |
29 Sep 2025 | $0.03 | $0.00 | 0.00% | 538,953 | $0.03 | $0.03 | $0.03 |
26 Sep 2025 | $0.03 | $0.00 | 0.00% | 635,807 | $0.03 | $0.03 | $0.03 |
25 Sep 2025 | $0.03 | $0.00 | 0.00% | 1,978,949 | $0.03 | $0.03 | $0.03 |
24 Sep 2025 | $0.03 | $0.01 | 45.45% | 8,951,440 | $0.02 | $0.03 | $0.02 |
23 Sep 2025 | $0.02 | $0.00 | 0.00% | 778,469 | $0.02 | $0.02 | $0.02 |
22 Sep 2025 | $0.02 | $0.00 | 0.00% | 1,554,279 | $0.02 | $0.02 | $0.02 |
19 Sep 2025 | $0.02 | $0.00 | 0.00% | 2,607,258 | $0.02 | $0.02 | $0.02 |
18 Sep 2025 | $0.02 | $0.00 | 0.00% | 824,395 | $0.02 | $0.02 | $0.02 |
17 Sep 2025 | $0.02 | $0.00 | 0.00% | 702,878 | $0.02 | $0.02 | $0.02 |
16 Sep 2025 | $0.02 | $0.00 | 0.00% | 1,913,209 | $0.02 | $0.02 | $0.02 |
15 Sep 2025 | $0.02 | $0.00 | 0.00% | 3,039,378 | $0.02 | $0.02 | $0.02 |
12 Sep 2025 | $0.02 | $0.00 | 0.00% | 13,438,130 | $0.02 | $0.02 | $0.02 |
11 Sep 2025 | $0.02 | $0.00 | 0.00% | 307,953 | $0.02 | $0.02 | $0.02 |
10 Sep 2025 | $0.02 | $0.00 | 0.00% | 310,058 | $0.02 | $0.02 | $0.02 |
09 Sep 2025 | $0.02 | $0.00 | 0.00% | 700,983 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
27 Jun 2025 | John Kelly | Issued | 1,621,622 | $24,324 |
Issue of securities.
|
27 Jun 2025 | John Kelly | Issued | 1,621,622 | $30,000 |
Issue of securities.
|
27 Jun 2025 | Anthony May | Issued | 540,541 | $10,000 |
Issue of securities.
|
27 Jun 2025 | Anthony May | Issued | 540,541 | $8,108 |
Issue of securities.
|
27 Jun 2025 | Patrick Cook | Issued | 540,541 | $10,000 |
Issue of securities.
|
27 Jun 2025 | Patrick Cook | Issued | 540,541 | $8,108 |
Issue of securities.
|
14 Apr 2025 | John Kelly | Expiry | 666,666 | $14,666 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr John Michael Kelly | FounderChief Executive OfficerManaging Director | Apr 2010 |
Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
|
Dr Cheri Louise Walker | Non-Executive Director | Nov 2022 |
Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. He is a member of the Risk Committee.
|
Mr Anthony May | Non-Executive Director | May 2025 |
Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a record in business leadership and strategic growth.
|
Mr Patrick Cook | Non-Executive Director | May 2025 |
Mr Cook is a Non-Executive Director and Chair with over 20 years of board level experience and over 30 years experience in senior executive positions in medical devices & point-of-care diagnostics sectors within multinational and listed biotechnology companies Mr Cook currently serves as Non-Executive Director & previously Chair, at Workplace Drug Testing Australasia Ltd and as Committee Member & previously Member of the Executive at Animal Ethics Committee QUT. He previously served as Non-Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld).
|
Mr Mathew Leslie Watkins | Company Secretary | Jun 2024 |
-
|
Mathew Leslie Watkins | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
GZ Family Holdings Pty Ltd | 79,787,536 | 12.48% |
Dalraida Holdings Pty Limited | 65,120,000 | 10.19% |
Global Health Investment Fund | 64,811,280 | 10.14% |
Mr Xiaoyi Lin | 11,880,000 | 1.86% |
Grand Challenges Canada | 11,390,824 | 1.78% |
Liverbird Pty Ltd | 10,931,653 | 1.71% |
Australia West Holdings Pty | 10,500,000 | 1.64% |
Australia North Holdings Pty | 9,580,000 | 1.50% |
ID&E Pty Ltd | 9,032,248 | 1.41% |
Mark Andrew Smith | 7,790,224 | 1.22% |
Mr Ian Fredrick Johnson | 7,506,080 | 1.17% |
John Michael Kelly | 7,370,248 | 1.15% |
Leo James Lynch | 7,321,121 | 1.15% |
Citicorp Nominees Pty Limited | 6,355,684 | 0.99% |
Mr Ankur Choudhary | 5,887,126 | 0.92% |
Ruth Karen Devney | 5,626,408 | 0.88% |
Sokolov Pty Ltd | 4,031,888 | 0.63% |
H & L Management Pty Ltd | 4,000,000 | 0.63% |
Rue Des Rocs Pty Ltd | 3,800,000 | 0.59% |
Miss Lisa Marie Mackenzie | 3,351,968 | 0.52% |